Drugs / Di-Dak-Sol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04851522 | Jun 2021 → Apr 2022 | radiodermatitis | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Di-Dak-Sol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04851522 ↗ |
| Route | Topical | “Topical solution applied externally.” NCT04851522 ↗ |